To Evaluate the Efficacy and Safety of QL2401 in Patients With Metabolic Dysfunction-associated Steatohepatitis and Liver Fibrosis (F2-F3)
Clinical trial NCT07620366 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07620366
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-06-01
- Primary completion
- 2027-06-01
- Enrollment
- 132
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.